Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.63 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.63 |
| ▸ | TNF | P01375 | 1/20 | 0.63 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.57 |
| ▸ | FDPS | P14324 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794361 | 0.84 | TDP1 (0.76) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL30564238 | 0.84 | TDP1 (0.76) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL6442808 | 0.84 | TDP1 (1.00) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL5913820 | 0.83 | TDP1 (0.81) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| Hydrochloric Acid SCHEMBL6946175 | 0.82 | TDP1 (0.66) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL1038315 | 0.81 | KDM4E (0.69) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL1645851 | 0.81 | TDP1 (0.70) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL131657 | 0.81 | TDP1 (0.70) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL3161153 | 0.81 | TDP1 (0.84) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL9814242 | 0.81 | TDP1 (0.84) | TDP1CYP11B1CYP11B2TNFEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003040103-A1 | β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | TDP1 1041/4885CYP11B1 525/4885CYP11B2 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.